Oncolytic virotherapy for multiple myeloma

Bibliography

• Albano A. Adaptation of rat myeloma cells to continuous culture and their susceptibility to enteroviruses, adenoviruses, and measles virus. Boll Ist Sieroter Milan 1962;41:599-607
   PubMedGoogle Scholar
• Kawa A, Arakawa S. The effect of attenuated vaccinia virus AS strain on multiple myeloma; A case report. Jpn J Exp Med 1987;57(1):79-81
   PubMedGoogle Scholar
• Meeker TC, Lay LT, Wroblewski JM, et al. Adenoviral vectors efficiently target cell lines derived from lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin's disease. Clin Cancer Res 1997;3:357-64
   PubMed Web of Science ®Google Scholar
• Ito T, Wang D-Q, Maru M, et al. Antitumor efficacy of vaccinia virus-modified tumor cell vaccine. Cancer Res 1990;50:6915-8
   PubMed Web of Science ®Google Scholar
• Phase I Trial: Vaccine Therapy with or without Cyclophosphamide in Treating Patients with Recurrent or Refractory Multiple Myeloma. Available from: www.clinicaltrials.gov/ct/show/NCT00450814?order=1 [last accessed January 18, 2008]
   Google Scholar
• Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002;9:961-6
   PubMed Web of Science ®Google Scholar
• Wen XY, Mandelbaum S, Li ZH, et al. Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7.1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther 2001;8(5):361-70
   PubMed Web of Science ®Google Scholar
• Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3(6):639-45
   PubMed Web of Science ®Google Scholar
• Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Human Gene Ther 2003;14:933-46
   PubMed Web of Science ®Google Scholar
• Heise C, Herminston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6(10):1134-9
   PubMed Web of Science ®Google Scholar
• Cascallo M, Capella G, Mazo A, Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003;63:5544-50
   PubMed Web of Science ®Google Scholar
• McCart JA, Wang ZH, Xu H, et al. Development of a melanoma-specific adenovirus. Mol Ther 2002;6(4):471-80
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Schuur ER, Lim HY, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559-63
   PubMed Web of Science ®Google Scholar
• Turturro F. Recombinant adenovirus-mediated cytotoxic genetherapy of lymphoproliferative disorders: is CAR important for the vector to ride. Gene Ther 2003;10(2):100-4
   PubMed Web of Science ®Google Scholar
• Dmitriev I, Kashentseva E, Rogers BE, et al. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 2000;74(15):6875-84
   PubMed Web of Science ®Google Scholar
• Li HJ, Everts M, Pereboeva L, et al. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic bispecific adapter. Cancer Res 2007;67(11):5354-61
   PubMed Web of Science ®Google Scholar
• Peng K-W, Donovan KA, Schneider U, et al. Oncolytic measles virus displaying a single chain antibody against CD38, a myeloma cell marker. Blood 2003;101(7):2557-62
   PubMed Web of Science ®Google Scholar
• Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003;9(11):1408-12
   PubMed Web of Science ®Google Scholar
• Strair R, Sheay W, Goodell L, et al. Adenovirus infection of primary malignant lymphoid cells. Leuk Lymphoma 2002;43(1):37-49
   PubMed Web of Science ®Google Scholar
• Moss B. Poxviridae: the viruses and their replication. In: Fields Virology. Knipe DM, Howley PM, editors. Philadelphia, Lippincott, Williams & Wilkins; 2001. p. 2849-84
   Google Scholar
• Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther 2005;11(2):180-95
   PubMed Web of Science ®Google Scholar
• Fenner F, Wittek R, Dumbell KR. The Orthopoxviruses. New York, Academic Press, Inc.; 1989. p. 143-70
   Google Scholar
• Moss B. Vaccinia Virus. A Tool for Research and Vaccine Development. Science 1991;252:1662-7
   PubMed Web of Science ®Google Scholar
• Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006;14(3):361-70
   PubMed Web of Science ®Google Scholar
• Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002;(9):1001-12
   PubMed Web of Science ®Google Scholar
• McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-7
   PubMed Web of Science ®Google Scholar
• Guo ZS, Naik A, O'Malley ME, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005;65(21):9991-8
   PubMed Web of Science ®Google Scholar
• Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341-8
   PubMed Web of Science ®Google Scholar
• Moss B, Earl PL. Expression of proteins in mammalian cells using vaccinia viral vectors. In: Ausubel FM, Brent R, Kingston RE, et al., editors. New York, NY: John Wiley. Curr Prot Mol Biol 1998;43:16.15.1-16.19.11.
   Google Scholar
• Griffin DE. Measles Virus. In: Fields Virology. Fields BN, Knipe DM, Howley PM, editors. Philadelphia, Lippincott, Williams, Wilkins; 2001. p. 1401-42
   Google Scholar
• Nakamura T, Russell SJ. Oncolytic measles viruses for cancer therapy. Expert Opin Biol Ther 2004;4(10):1685-92
   PubMed Web of Science ®Google Scholar
• Anderson BD, Nakamura T, Russell SJ, Peng K-W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004;64:4919-26
   PubMed Web of Science ®Google Scholar
• Ong HT, Timm MM, Greipp PR, et al. Oncolytic measels virus targets high CD46 expression on muliple myeloma cells. Exp Hematol 2006;34:713-20
   PubMed Web of Science ®Google Scholar
• Radecke F, Spielhofer P, Schneider H, et al. Rescue of measles viruses from cloned DNA. EMBO J 1995;14(23):5773-84
   PubMed Web of Science ®Google Scholar
• Nakamura T, Peng K-W, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles virus. Nat Biotechnol 2005;23(2):209-14
   PubMed Web of Science ®Google Scholar
• Dingli D, Peng K-W, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measels virus expressing the thyroidal sodium iodide symporter. Blood 2004;103(5):1641-6
   PubMed Web of Science ®Google Scholar
• Rose JK, Whitt MA. Rhabdoviridae: The Viruses and their Replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM, editors. Philadelphia, Lippincott Williams & Wilkins; 2001. p. 1221-43
   Google Scholar
• Stojdl DF, Abraham N, Knowles S, et al. The murine double-stranded RNA-dependent protein kinase PKR is required for resistence to vesicular stomatitis virus. J Virol 2000;74(20):9580-5
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003;4:263-75
   PubMed Web of Science ®Google Scholar
• Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or Myc function and involves the induction of apoptosis. J Virol 2001;75(7):3474-9
   PubMed Web of Science ®Google Scholar
• Noser JA, Mael AA, Sakuma R, et al. The ras/raf1/mek/erk signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther 2007;15(8):1531-6
   PubMed Web of Science ®Google Scholar
• Lichty BD, Power AT, Stojdl DF, Bell JC. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004;10(5):210-6
   PubMed Web of Science ®Google Scholar
• Goel A, Carlson SK, Classic KL, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta 51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodidie symporter gene. Blood 2007;110(7):2342-50
   PubMed Web of Science ®Google Scholar
• Nibert ML, Schiff LA. Reoviruses and their Replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM, editors. Philadelphia, Lippincott Williams & Wilkins; 2001. p. 1679-720
   Google Scholar
• Coffey MC, Strong JE, Forsyth PA, Lee PWK. Reovirus therapy of tumors with activated ras pathway. Science 1998;282:1332-4
   PubMed Web of Science ®Google Scholar
• Norman KL, Hirasawa K, Yang A-D, et al. Reovirus oncolysis: the ras/ralGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004;101(30):11099-104
   PubMed Web of Science ®Google Scholar
• Alain T, Hirasawa K, Pon KJ, et al. Reovirus therapy of lymphoid malignancies. Blood 2002;100(12):4146-53
   PubMed Web of Science ®Google Scholar
• Thirukkumaran CM, Luider JM, Stewart DA, et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 2003;102(1):377-87
   PubMed Web of Science ®Google Scholar
• Shafren DR, Au GG, Nguyen T, et al. Systemic therapy of malignant human melanoma tumours by a common cold-producing enterovirus, coxsackievirus A21. Clin Cancer Res 2004;10:53-60
   PubMed Web of Science ®Google Scholar
• Au GG, Lincz LF, Enno A, Shafren DR. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol 2007;137:133-41
   PubMed Web of Science ®Google Scholar
• Racaniello VR. Picornaviridae: The Viruses and their Replication. In: Fields Virology. Knipe DM, Howley PM, editors. Philadelphia, Lippincott, Williams & Wilkins; 2001. p. 685-722
   Google Scholar
• Shafren DR. Viral cell entry induced by cross-linked decay-accelerating factor. J Virol 1998;72(11):9407-12
   PubMed Web of Science ®Google Scholar
• Shafren DR, Dorahy DJ, Ingham RA, et al. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 1997;71(6):4736-43
   PubMed Web of Science ®Google Scholar
• Alexander DD, Mink PJ, Adami H-O, et al. Multiple myeloma: a review of the epidemilogic literature. Int J Cancer 2007;120:40-61
   PubMed Web of Science ®Google Scholar
• Multiple myeloma/other plasma cell neoplasms. Available from: http://www.cancer.gov/cancertopics/types/myeloma [last accessed January 18, 2008]
   Google Scholar
• Canadian Cancer Statistics 2007. Toronto, Canada, Canadian Cancer Society/National Cancer Institute of Canada. 2007. Available from: 129.33.170.32/vgn/images/portal/cit_86751114/36/15/1816216925cw_2007stats_en.pdf [last accessed January 18, 2008]
   Google Scholar
• McElwain TJ, Selby PJ, Gore ME, et al. High-dose chemotherapy and autologous bone marrow transplantation for myeloma. Eur J Haematol Suppl 1989;51:152-6
   PubMedGoogle Scholar
• Hideshima T, Richardson P, Chauhan D, et al. The proteosome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistence in human multiple myeloma cells. Cancer Res 2001;61:3071-6
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Novel biological therapies for the treatment of multiple myeloma. Best Practice & Res Clin Hematol 2005;18(4):619-34
   PubMed Web of Science ®Google Scholar
• Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105(7):2941-8
   PubMed Web of Science ®Google Scholar
• Trudel S, Li ZH, Rauw J, et al. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007;109:5430-8
   PubMed Web of Science ®Google Scholar
• Fonseca R, Stewart AK. Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther 2007;6(3):802-10
   PubMed Web of Science ®Google Scholar
• Dingli D, Peng K-W, Harvey ME, et al. Interaction of measles virus vectors wirh Auger electron emitting radioisotopes. Biochem Biophys Res Comm 2005;337:22-9
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase 1 trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B cell malignancies. J Clin Oncol 2005;23:6719-29
   PubMed Web of Science ®Google Scholar
• Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001;98(7):2002-7
   PubMed Web of Science ®Google Scholar
• Lichty BD, Stojdl DF, Taylor RA, et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematological malignancy. Human Gene Ther 2004;15:821-31
   PubMed Web of Science ®Google Scholar
• Hallak LK, Merchan JR, Storgard CM, et al. Targeted measels virus vector displaying echistatin infects endothelial cells via αvβ3 and leads to tumor regression. Cancer Res 2005;65(12):5292-300
   PubMed Web of Science ®Google Scholar
• Ong HT, Hasegawa K, Dietz AB, et al. Evaluation of T cells as carriers for systemic measels virotherapy in the presence of antiviral antibodies. Gene Ther 2007;14:324-33
   PubMed Web of Science ®Google Scholar
• Iankov I, Blechacz B, Liu C, et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measels viruses in cancer virotherapy. Mol Ther 2007;15(1):114-22
   PubMed Web of Science ®Google Scholar
• Grandvaux N, tenOever BR, Servant MJ, Hiscott J. The interferon viral response: from viral invasion to evasion. Curr Opin Infect Dis 2002;15:259-67
   PubMed Web of Science ®Google Scholar
• Haralambieva I, Iankov I, Hasegawa K, et al. Engineering oncolytic measels virus to circumvent the intracellular innate immune response. Mol Ther 2007;15(3):588-97
   PubMed Web of Science ®Google Scholar
• McCart JA, Mehta N, Scollard D, et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther 2004;10(3):553-61
   PubMed Web of Science ®Google Scholar
• Dingli D, Kemp BJ, O'Connor MK, et al. Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously trabsfected tumor. Mol Imaging Biol 2006;8:16-23
   PubMed Web of Science ®Google Scholar
• Chauhan D, Pandey P, Ogata A, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997;15:837-43
   PubMed Web of Science ®Google Scholar
• Strömberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004;103:3138-47
   PubMed Web of Science ®Google Scholar
• Stanford MM, Barrett JW, Nazarian SH, et al. Oncolytic virotherapy synergy with signaling inhibitors: Rapamycin increases myxoma virus tropism for human cells. J Virol 2007;81(3):1251-60
   PubMed Web of Science ®Google Scholar
• Johnson TR, Stone K, Nikrad M, et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003;22(32):4953-63
   PubMed Web of Science ®Google Scholar